Melatonin protects against streptozotocin-induced diabetic cardiomyopathy through the mammalian target of rapamycin (mTOR) signaling pathway

Creative Commons License

Kandemir Y. B., Tosun V., GÜNTEKİN Ü.

ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, cilt.28, sa.9, ss.1171-1177, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 28 Sayı: 9
  • Basım Tarihi: 2019
  • Doi Numarası: 10.17219/acem/103799
  • Dergi Adı: ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1171-1177
  • Anahtar Kelimeler: melatonin, diabetic cardiomyopathy, mammalian target of rapamycin, NLRP3 INFLAMMASOME ACTIVATION, LEFT-VENTRICULAR MASS, HEART, METABOLISM, PRESERVATION, RECOVERY, RATS
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Background. Several studies demonstrated that the overexpression of mammalian target of rapamycin (mTOR) signaling protein is associated with cardiomyopathy. However, the effect of mTOR on the heart in hyperglycemic condition is still controversial.